NASDAQ / LIVE COMPANY INTELLIGENCE

Mineralys Therapeutics, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERMLYS
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / MLYS COVERAGE

What’s moving Mineralys Therapeutics, Inc. now

Current reporting with the operating signal separated from the noise.

01
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?

Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?

Investors are testing whether Mineralys Therapeutics, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
02
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

The story matters when it changes Mineralys Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

The story matters when it changes Mineralys Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

The story matters when it changes Mineralys Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know

The story matters when it changes Mineralys Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest MLYS filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-06 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-10 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-12 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-06-03 · Period 2026-06-03SEC ↗8-KMaterial company eventFiled 2026-06-03 · Period 2026-06-02SEC ↗8-KMaterial company eventFiled 2026-05-22 · Period 2026-05-21SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-08 · Period 2026-05-21SEC ↗4Official SEC filingFiled 2026-07-23 · Period 2026-07-21SEC ↗
EARNINGS / QUARTERLY TRACKER

Mineralys Therapeutics, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.